A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 681257 Administered Subcutaneously to Healthy Volunteers With Elevated Lipoprotein(a)

Trial Profile

A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 681257 Administered Subcutaneously to Healthy Volunteers With Elevated Lipoprotein(a)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs IONIS APOA-LRx (Primary)
  • Indications Hyperlipoproteinaemias
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 30 Mar 2017 Results published in an Akcea Therapeutics media release.
    • 22 Sep 2016 According to an Akcea Therapeutics media release, results from this study were published in The Lancet.
    • 22 Sep 2016 Results published in an Akcea Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top